Highbridge Capital Management’s Achillion Pharmaceuticals ACHN Stock Holding History

Highbridge Capital Management’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-35,478	Closed	-$149K	–	1783
2017 Q1	$149K	Buy	+35,478	New	+$147K	﹤0.01%	1352
2016 Q4	–	Sell	-154,916	Closed	-$1.25M	–	1740
2016 Q3	$1.25M	Buy	154,916 +126,044	+437%	+$1.07M	0.02%	510
2016 Q2	$225K	Buy	+28,872	New	+$248K	﹤0.01%	1192
2015 Q3	–	Sell	-291,981	Closed	-$2.59M	–	1929
2015 Q2	$2.59M	Buy	291,981 +31,504	+12%	+$298K	0.03%	465
2015 Q1	$2.57M	Buy	+260,477	New	+$3.25M	0.04%	472
2014 Q4	–	Sell	-51,453	Closed	-$513K	–	1538
2014 Q3	$513K	Sell	51,453 -37,218	-42%	-$345K	0.01%	849
2014 Q2	$671K	Buy	88,671 +39,806	+81%	+$159K	0.01%	672
2014 Q1	$161K	Buy	+48,865	New	+$171K	﹤0.01%	980
2013 Q4	–	Sell	-50,743	Closed	-$153K	–	1429
2013 Q3	$153K	Buy	+50,743	New	+$348K	﹤0.01%	1204

Other funds holding ACHN

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Highbridge Capital Management's ACHN Position: Q2 2017 in Review

Highbridge Capital Management sold out of Achillion Pharmaceuticals (ACHN) in Q2 2017, closing a stake of 35,478 shares — an estimated $149K sold.

Highbridge Capital Management first reported a position in ACHN in Q3 2013 and held it in 9 quarters. The position peaked at $2.59M in Q2 2015. 129 funds tracked by Wall St. Rank hold ACHN as of Q2 2017.

Highbridge Capital Management reported no remaining Achillion Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Highbridge Capital Management sold 35,478 Achillion Pharmaceuticals shares in Q2 2017, an estimated $149K.
Highbridge Capital Management first reported a position in Achillion Pharmaceuticals in Q3 2013 and held it in 9 quarters.
Highbridge Capital Management's Achillion Pharmaceuticals position peaked at $2.59M in Q2 2015.
129 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q2 2017.

Based on Highbridge Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.